Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncolytics Biotech Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.069 -- 00:00:04.351 are ongoing business development initiatives, and other statements related to anticipated 00:00:04.351 -- 00:00:07.993 developments in the company's business. These statements are based on management's current 00:00:07.993 -- 00:00:12.715 expectations and beliefs and are subject to a number of factors which involve none and 00:00:12.715 -- 00:00:17.417 unknown risks, delays, uncertainties, and other factors not under the company's control 00:00:17.417 -- 00:00:21.699 that may cause actual results, performance, or achievements of the company to be materially 00:00:21.699 -- 00:00:25.681 different from the results, performance, or expectations implied by these four looking 00:00:25.681 -- 00:00:30.344 statements. In any forward-looking statement in which oncologists express an expectation 00:00:30.344 -- 00:00:35.286 or belief as to future results, such expectations or beliefs are expressed in good faith, 00:00:35.286 -- 00:00:38.427 and our beliefs have a reasonable basis, but there can be no assurance that the statement 00:00:38.427 -- 00:00:40.889 or expectation or belief will be achieved. 00:00:40.889 -- 00:00:45.071 These factors include results of current or pending clinical trials, risks associated 00:00:45.071 -- 00:00:50.733 with intellectual property protection, financial projections, actions by regulatory agencies, 00:00:50.733 -- 00:00:54.901 and those other factors detailed in the company's filings with CDAR and the SEC. 00:00:54.901 -- 00:00:58.382 Unclaims does not undertake any obligation to update these forward-looking statements 00:00:58.382 -- 00:01:02.464 except as required by applicable laws. Now, I'm pleased to introduce the members of our 00:01:02.464 -- 00:01:05.965 management team who are joining me to discus...